# GPT 5.2 Review - Reviewer 3/3 (Parallel)

**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Reasoning effort:** medium
**Timestamp:** 2026-01-24T10:36:50.889564
**Review mode:** Parallel (3 independent reviewers)
**Response ID:** resp_0a45512c98cd857c00697492210fdc8194b9fe024c98aec819
**Tokens:** 8208 in / 5514 out
**Response SHA256:** 6570eee683ef1244

---

## Referee Report (top general-interest journal standard)

### Summary
The paper asks a clear and policy-relevant question: do state dental therapy authorization laws increase population oral health access? Using BRFSS/NOHSS state aggregates (2012–2020) and staggered DiD with Callaway–Sant’Anna (CS), the paper reports a **negative ATT of −1.3pp** on adult annual dental visits (Table 3; Results §5.3, p. 12–13), with no statistically significant pre-trend at the only available pre-event point (Event study §5.2, p. 11–12).

This is an interesting and potentially publishable topic, but **the current design and evidence base are not yet credible for a top journal**. The biggest issues are (i) **outcome and treatment measurement** (authorization vs implementation; aggregate outcome with sampling error; COVID-period confounding), (ii) **weak pre-trends diagnostics due to extremely short pre-periods and only five time points**, and (iii) **policy endogeneity** that is acknowledged but not addressed empirically. The paper reads like a careful working paper, but it is not at “AER/QJE/JPE/ReStud/Ecta/AEJ:EP” evidentiary standards yet.

---

# 1. FORMAT CHECK

### Length
- The PDF excerpt shows pages **1–18** (including appendices). Main text appears to end around p. **15** with appendices thereafter.
- **FAIL for top-journal submission standard**: it is **below 25 pages of main text** (excluding refs/appendix). You need either (i) a substantially deeper empirical section (preferred) or (ii) additional data, heterogeneity, mechanisms, and robustness that naturally expand the paper.

### References
- The reference list is **too thin** for a top journal. It cites CS (2021) and Goodman-Bacon (2021), but omits several now-standard staggered DiD/event-study references and essentially all closely related “mid-level provider/scope-of-practice” policy evaluation work.
- Domain references are mostly descriptive/government reports (CDC, HRSA, NASEM, NASHP). That is fine for background, but **you need peer-reviewed economics/health economics work** on dental coverage, provider supply, and scope-of-practice reforms.

### Prose (paragraph form vs bullets)
- Major sections (Intro, Empirical Strategy, Results, Discussion) are in paragraphs.
- Background includes bullet lists (scope of practice; §2.2 p. 4–5). That’s acceptable, but avoid bullets for core argumentation.

### Section depth (3+ substantive paragraphs each)
- **Intro (§1, p. 2–4):** ~3–5 paragraphs, OK.
- **Background (§2, p. 4–6):** subsections are short; §2.3 is very brief. Borderline.
- **Data (§3, p. 6–8):** reasonably structured; could be deeper on measurement.
- **Results (§5, p. 10–13):** short; needs far more depth (heterogeneity, robustness, alternative outcomes, sensitivity).
- **Discussion (§6, p. 13–14):** mostly interpretive; needs more evidence-backed mechanism tests.

### Figures
- Figures shown have axes and visible data. However:
  - **Event study figure (Fig. 2, p. 11):** CI band is very wide at later horizons; fonts look small; include exact coefficient values in a table as well (not only the figure).
  - **State-level trends (Fig. 3, p. 17):** appears as small multiples; readability may be poor in print—needs larger panels or fewer states per page.

### Tables
- Tables 1–3 have real numbers; no placeholders. Good.
- But you do **not** provide regression-style output tables for group-time ATTs/event-study coefficients. Top journals typically expect a table with each event-time coefficient + SE/CI.

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

### (a) Standard errors
- **PASS (bare minimum):** Table 3 reports ATT with SE and p-values; clustered at state level (Table 3 notes, p. 12–13). Event-study figure includes 95% CI shading.
- **But not sufficient for top-journal inference**:
  1. With **49 clusters** and few treated states (9), conventional cluster-robust SEs can be unreliable; you should report **wild cluster bootstrap** p-values (or randomization/permutation inference) for the main ATT and key event times.
  2. The outcome is **a survey-based estimate** (NOHSS state aggregates). Each state-year outcome has **sampling error**, yet you treat it as measured without error. At minimum, do **precision weighting** (inverse-variance weighting using NOHSS/BRFSS SEs if available) or move to **microdata BRFSS** and estimate at the individual level with survey weights and state clustering.

### (b) Significance testing
- **PASS:** p-values shown (Table 3; §5.2 pretrend test p=0.12).

### (c) Confidence intervals
- **PASS:** Table 3 has 95% CI; event study has CI shading.

### (d) Sample sizes
- **Partial PASS / borderline:** You clearly state N=245 state-years for the main estimation sample and describe treated/control composition (§3.3 p. 7–8; Table 3 notes).  
- **However**, you do not report effective N by cohort-time cell nor the number of observations contributing to each event-time estimate (important because later cohorts mechanically drop out).

### (e) DiD with staggered adoption
- **PASS:** You avoid TWFE pitfalls and use Callaway–Sant’Anna; you state you avoid already-treated units as controls (§4.2 p. 8–9). This is correct.

### (f) RDD
- Not applicable.

**Bottom line on methodology:** You clear the “not unpublishable” bar on *basic* inference reporting, but the inference and measurement choices are **not** yet at top-journal standards given (i) few treated units, (ii) aggregate outcomes with sampling error, and (iii) high sensitivity to 2020 and short panels.

---

# 3. IDENTIFICATION STRATEGY

### Credibility
The design is **not yet credible as causal** for a general-interest journal.

Key threats (some acknowledged, none convincingly handled):

1. **Authorization ≠ implementation (severe treatment mismeasurement).**  
   You code treatment as the first BRFSS period at/after legislative authorization (§3.2–§4.3, p. 6–10). But authorization often precedes:
   - rulemaking,
   - training program creation,
   - licensure pipeline,
   - actual employment and scope utilization,
   - Medicaid reimbursement changes.
   
   If “treatment” is mostly symbolic in 0–4 years, the DiD estimates are not interpretable as the effect of actual dental therapist supply.

2. **Very weak pre-trends diagnostics.**  
   You have only **five periods** (2012, 2014, 2016, 2018, 2020). For key early adopters:
   - Maine (2014 cohort) has essentially **one pre period** (2012).
   - Vermont (2016) has two pre periods (2012, 2014).
   
   Your event study admits **only one pre coefficient** used in the parallel trends test (§5.2 p. 11–12). A single pre point with p=0.12 is not persuasive evidence of parallel trends.

3. **COVID-19 is an enormous confounder (2020 outcome period).**  
   Dental utilization in 2020 was disrupted dramatically and heterogeneously by state policy and local conditions. Yet 2020 is:
   - a key post period for many treated cohorts, and
   - *the treatment cohort* for multiple states (ID, NV, OR, WA; Table 1 p. 5).
   
   This is a first-order threat: the negative ATT could be partly a “treated-states had different COVID shutdowns/behavior” effect. A top journal will demand either:
   - dropping 2020 (and acknowledging power loss), or
   - explicit controls/interaction terms for COVID policy intensity, mobility, local pandemic severity, and dental office closure stringency (ideally), or
   - an alternative outcome window not dominated by 2020.

4. **Policy endogeneity / reverse causality is central, not peripheral.**  
   You acknowledge reverse causation (§6.1 p. 13–14) but do not test it. In a general-interest outlet, “this may reflect reverse causation” is not acceptable as the main takeaway. You need an empirical strategy that either:
   - plausibly addresses endogeneity (IV, border discontinuity, synthetic control with rich predictors, negative control outcomes), or
   - explicitly reframes the paper as documenting **policy adoption as a response** (political economy paper), not causal effects.

5. **Confounding concurrent policies (Medicaid dental benefits; workforce scope).**  
   States adopting dental therapy may also change Medicaid adult dental benefits, reimbursement, managed care, FQHC funding, or dentist scope rules around the same time (§4.4 p. 9). Without controlling for these, you cannot attribute changes to dental therapy authorization.

### Placebos and robustness
- Robustness is minimal: one alternative control group definition (Appendix B; p. 17).
- Missing robustness checks expected at this level:
  - Leave-one-treated-state-out sensitivity.
  - Excluding 2020.
  - Cohort-specific ATTs (not only pooled).
  - Alternative outcome definitions (e.g., cost barrier, unmet need, ED dental visits).
  - “Fake adoption” placebo years for never-treated states.
  - Sensitivity to including Minnesota via alternative methods (e.g., SCM for Minnesota only; or dropping early cohorts and analyzing later adopters where pre-periods exist).

### Do conclusions follow?
- The conclusion currently overreaches: “authorization is associated with a decrease” is fine descriptively, but “caution against expecting improvements from authorization alone” is **not causally established** given endogeneity and COVID confounding. The paper must either fix identification or narrow claims substantially.

---

# 4. LITERATURE (missing references + BibTeX)

### Methodology literature (missing and important)
You cite Callaway–Sant’Anna and Goodman-Bacon. For a top journal you should also cite:

1) **Sun & Abraham (heterogeneous treatment effects in event studies)**
```bibtex
@article{SunAbraham2021,
  author  = {Sun, Liyang and Abraham, Sarah},
  title   = {Estimating Dynamic Treatment Effects in Event Studies with Heterogeneous Treatment Effects},
  journal = {Journal of Econometrics},
  year    = {2021},
  volume  = {225},
  number  = {2},
  pages   = {175--199}
}
```

2) **de Chaisemartin & D’Haultfœuille (TWFE pitfalls and alternatives)**
```bibtex
@article{deChaisemartinDHaultfoeuille2020,
  author  = {de Chaisemartin, Cl{\'e}ment and D'Haultf{\oe}uille, Xavier},
  title   = {Two-Way Fixed Effects Estimators with Heterogeneous Treatment Effects},
  journal = {American Economic Review},
  year    = {2020},
  volume  = {110},
  number  = {9},
  pages   = {2964--2996}
}
```

3) **Roth (pre-trends, power, and parallel trends testing)**
```bibtex
@article{Roth2022,
  author  = {Roth, Jonathan},
  title   = {Pretest with Caution: Event-Study Estimates after Testing for Parallel Trends},
  journal = {American Economic Review: Insights},
  year    = {2022},
  volume  = {4},
  number  = {3},
  pages   = {305--322}
}
```

4) (Optional but increasingly expected) **Borusyak, Jaravel & Spiess (imputation estimator / event-study design)**
```bibtex
@techreport{BorusyakJaravelSpiess2021,
  author      = {Borusyak, Kirill and Jaravel, Xavier and Spiess, Jann},
  title       = {Revisiting Event Study Designs: Robust and Efficient Estimation},
  institution = {NBER},
  year        = {2021},
  number      = {w28816}
}
```

### Substantive policy literature you should engage
A top economics journal will expect you to connect dental therapy to the broader evidence on scope-of-practice and mid-level providers (NPs/PAs). For example:

- **Kleiner et al. on nurse practitioner independence and access**
```bibtex
@article{KleinerMarierParkWing2016,
  author  = {Kleiner, Morris M. and Marier, Allison and Park, Kyoungwon and Wing, Coady},
  title   = {Relaxing Occupational Licensing Requirements: Analyzing Wages and Prices for a Medical Service},
  journal = {Journal of Law and Economics},
  year    = {2016},
  volume  = {59},
  number  = {2},
  pages   = {261--291}
}
```

You also need to cite and discuss the (largely health-policy) empirical literature on dental therapists specifically (quality, utilization, supply, FQHC deployment). Right now the paper cites mostly reports and one Minnesota evaluation; that is not enough. If you cannot find economics-journal papers, then you must (i) comprehensively review Health Affairs / JDR / J Public Health Dentistry evidence and (ii) clearly explain how your quasi-experimental design adds to that literature.

---

# 5. WRITING QUALITY (CRITICAL)

### Prose vs bullets
- Generally acceptable: the core sections are paragraph-based.
- However, several sections read like a technical memo, not a polished general-interest narrative (especially §4 and §5).

### Narrative flow
- The motivation is clear, but the paper’s “twist” (negative effect) is introduced early without enough scaffolding:
  - What exactly is the policy lever—authorization, licensure, practice in safety-net settings?
  - Who should be affected first (Medicaid adults? rural areas? FQHC patients)?
  - What is the model of how authorization translates into utilization?

A top-journal reader will want a simple conceptual framework (even a one-page model or logic chain) to interpret sign and timing.

### Sentence-level clarity and accessibility
- Generally readable.
- But magnitudes are not contextualized enough: What does −1.3pp mean relative to baseline? You report baseline means (Table 2), but you do not translate this into relative change or implied number of adults.

### Figures/tables as stand-alone objects
- Need publication-quality:
  - Each figure should explicitly state: estimator, comparison group, weights, clustering, and N contributing to each point.
  - Add a table for event-time coefficients with SEs.

---

# 6. CONSTRUCTIVE SUGGESTIONS (what would make this publishable)

To reach AEJ:EP / general-interest standards, you likely need to **rebuild the empirical core** around stronger measurement and identification:

### A. Measure implementation, not just authorization
- Collect **counts of dental therapists per state-year** (licensure data; OHWRC; state boards) and estimate dose-response:
  - Event study on “therapists per 100k” rather than a binary law.
  - Instrument therapist growth with authorization timing only if you can argue exclusion (hard), or at least show first-stage.

### B. Move from NOHSS aggregates to BRFSS microdata
- Use individual-level BRFSS:
  - outcome: dental visit last year;
  - covariates: age, sex, race/ethnicity, education, income, insurance;
  - survey weights; cluster at state level.
- This allows:
  - heterogeneity (low-income, rural, Medicaid proxy groups),
  - compositional checks (did respondent mix change?),
  - richer pre-trends diagnostics (at least within subgroups).

### C. Deal head-on with 2020 (COVID)
At minimum:
- Re-estimate dropping 2020 entirely.
- Or add controls for COVID intensity/policies (shutdown timing; dental office closure guidance; mobility declines; cumulative deaths).
- A convincing paper will show that results are not an artifact of 2020.

### D. Expand outcomes beyond “annual dental visit”
If the policy is aimed at underserved access, dental visits may be too coarse. Add:
- cost barrier / inability to afford care (BRFSS has cost-related foregone care items in some years/modules),
- self-reported oral health status,
- ED visits for nontraumatic dental conditions (HCUP state ED data, if feasible),
- Medicaid dental claims utilization (if accessible for adopting states),
- dentist supply / HPSA metrics to test mechanisms and compositional shifts.

### E. Stronger identification / falsification
- **Synthetic control** (Abadie et al.) for early adopters with clearer pre-trends (e.g., Maine, Vermont), then aggregate evidence across cases.
- Border-county design: compare counties near borders of adopting vs non-adopting states (requires county-level outcomes; BRFSS may be too small, but other data might work).
- Placebo policies: assign fake adoption years to never-treated states to show your pipeline doesn’t “find effects” mechanically.

### F. Clarify estimands and timing
- With biennial “past year visit” measures, define precisely what “post” means (you partially do, but implications need to be explicit). Consider lags (2–6 years) as primary, not t=0.

---

# 7. OVERALL ASSESSMENT

### Key strengths
- Important policy question with clear welfare relevance.
- Correctly avoids TWFE pitfalls and uses CS staggered DiD (§4.2).
- Transparent about Minnesota being always-treated and dropped (§4.3).
- Honest discussion of endogeneity threats (§6.1), which is good scientific practice.

### Critical weaknesses (publication blockers)
1. **Treatment mismeasurement:** authorization is not implementation; no evidence therapists actually entered practice in the window.
2. **Extremely limited time series (T=5) and weak pre-trend evidence** (only one usable pre coefficient).
3. **2020 confounding is likely first-order** and not handled.
4. **Endogeneity is acknowledged but not addressed**, yet causal language remains prominent.
5. **Literature positioning is incomplete**, especially relative to modern DiD/event-study diagnostics and scope-of-practice empirical work.

### Specific improvements
- Switch to microdata; add subgroup analysis; drop/handle 2020; measure therapist supply; add outcomes; add stronger falsification and sensitivity; deepen literature and narrative.

---

DECISION: REJECT AND RESUBMIT